OmniAb, Inc. (OABI)
NASDAQ: OABI · Real-Time Price · USD
2.385
-0.035 (-1.45%)
Mar 31, 2025, 10:47 AM EDT - Market open

Company Description

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.

The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts.

Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics.

The company's animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.

The company has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb’s antibody discovery platform.

OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

OmniAb, Inc.
OmniAb logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 114
CEO Matthew Foehr

Contact Details

Address:
5980 Horton Street, Suite 600
Emeryville, California 94608
United States
Phone 510 250 7800
Website omniab.com

Stock Details

Ticker Symbol OABI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001846253
CUSIP Number 68218J103
ISIN Number US68218J1034
SIC Code 8731

Key Executives

Name Position
Matthew W. Foehr President, Chief Executive Officer and Director
Kurt A. Gustafson Executive Vice President of Finance and Chief Financial Officer
Charles S. Berkman J.D. Chief Legal Officer and Secretary
Cia McCaffrey Vice President of People and Talent
Dr. Bill Harriman Ph.D. Senior Vice President of Antibody Discovery
Marie-Cecile van de Lavoir D.V.M., Ph.D. Senior Vice President of Technical Operations and Genetics
Dr. Christel Iffland Ph.D. Senior Vice President of Antibody Technologies
Dr. Yasmina Noubia Abdiche Ph.D. Senior Vice President of Exploratory Research
Donna Ventura CPA Senior Vice President and Corporate Controller

Latest SEC Filings

Date Type Title
Mar 18, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 18, 2025 144 Filing
Feb 18, 2025 144 Filing
Feb 18, 2025 144 Filing
Jan 21, 2025 144 Filing
Jan 21, 2025 144 Filing
Jan 21, 2025 144 Filing
Dec 9, 2024 144 Filing